BR112019009399A2 - atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano - Google Patents

atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano

Info

Publication number
BR112019009399A2
BR112019009399A2 BR112019009399A BR112019009399A BR112019009399A2 BR 112019009399 A2 BR112019009399 A2 BR 112019009399A2 BR 112019009399 A BR112019009399 A BR 112019009399A BR 112019009399 A BR112019009399 A BR 112019009399A BR 112019009399 A2 BR112019009399 A2 BR 112019009399A2
Authority
BR
Brazil
Prior art keywords
bacterial
attenuation
folate
virulence
bacterium
Prior art date
Application number
BR112019009399A
Other languages
English (en)
Inventor
Ingebritson Alaina
De Greeff Astrid
Neubauer Axel
Elizabeth Smith Hilda
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of BR112019009399A2 publication Critical patent/BR112019009399A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção refere-se a infecções bacterianas, vacinas direcionadas contra essas infecções e vacinas bacterianas. mais particularmente, a invenção refere-se a vacinas direcionadas contra infecções por streptococcus em porcos. é fornecido um mutante ¿folt de uma bactéria com capacidade reduzida para transportar folato, em que a capacidade foi reduzida através da deleção da funcionalidade da função transportadora de folato (folt). também é fornecido um método para reduzir a virulência de uma bactéria, que compreende reduzir a capacidade da bactéria para transportar folato.
BR112019009399A 2016-11-11 2017-11-10 atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano BR112019009399A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16198361 2016-11-11
PCT/US2017/061170 WO2018089841A1 (en) 2016-11-11 2017-11-10 Attenuating bacterial virulence by attenuating bacterial folate transport

Publications (1)

Publication Number Publication Date
BR112019009399A2 true BR112019009399A2 (pt) 2019-10-08

Family

ID=57396264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009399A BR112019009399A2 (pt) 2016-11-11 2017-11-10 atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano

Country Status (20)

Country Link
US (2) US11684663B2 (pt)
EP (2) EP4159231A1 (pt)
JP (2) JP6982616B2 (pt)
KR (1) KR102674702B1 (pt)
CN (1) CN110582296B (pt)
AU (1) AU2017357813A1 (pt)
BR (1) BR112019009399A2 (pt)
CA (1) CA3043039A1 (pt)
CL (1) CL2019001275A1 (pt)
DK (1) DK3538143T3 (pt)
EA (1) EA201991126A1 (pt)
ES (1) ES2926543T3 (pt)
HU (1) HUE060176T2 (pt)
MX (2) MX2019005499A (pt)
MY (1) MY201256A (pt)
PH (1) PH12019501019A1 (pt)
PL (1) PL3538143T3 (pt)
PT (1) PT3538143T (pt)
RS (1) RS63524B1 (pt)
WO (1) WO2018089841A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991126A1 (ru) * 2016-11-11 2019-11-29 Снижение вирулентности бактерий путем снижения транспорта фолата у бактерий
WO2021035421A1 (en) * 2019-08-23 2021-03-04 Chifeng Pharmaceutical Co., Ltd. Folate producing strain and the preparation and application thereof
WO2021245071A1 (en) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
WO2021250010A1 (en) 2020-06-08 2021-12-16 Mv Biotherapeutics Sa Atp-hydrolyzing enzyme useful for treating dysbiosis
CN112813085B (zh) * 2021-03-05 2023-03-31 昆明理工大学 焦磷酸酶基因的用途
CN112961878B (zh) * 2021-03-08 2023-04-25 昆明理工大学 一种植物乳杆菌的基因在叶酸生物生成中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6229001B1 (en) * 1997-01-03 2001-05-08 Southern Research Institute Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase
US5882898A (en) 1997-08-29 1999-03-16 Smithkline Beecham Corporation Streptococcus pneumoniae polynucleotides which encode folyl-polyglutamate synthetase (FPGS) polypeptides
DK1098980T3 (da) * 1998-07-22 2014-09-29 Stichting Dienst Landbouwkundi Streptococcus suis-vacciner og diagnostiske tests
EP1205552A1 (en) 2000-11-09 2002-05-15 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Virulence of streptococci, involving ORFs from Streptococcus suis
DE102005049527B4 (de) * 2005-10-17 2013-05-08 Forschungszentrum Jülich GmbH Verfahren zur Herstellung von L-Serin, Gensequenz, Vektoren sowie Mikroorganismus
CN106085936B (zh) * 2016-06-14 2019-02-26 华中农业大学 一种猪链球菌2型10基因缺失株及应用
EA201991126A1 (ru) * 2016-11-11 2019-11-29 Снижение вирулентности бактерий путем снижения транспорта фолата у бактерий

Also Published As

Publication number Publication date
CL2019001275A1 (es) 2019-09-06
PT3538143T (pt) 2022-09-06
JP2022036982A (ja) 2022-03-08
MY201256A (en) 2024-02-14
EA201991126A1 (ru) 2019-11-29
JP6982616B2 (ja) 2021-12-17
US11684663B2 (en) 2023-06-27
US20220226456A1 (en) 2022-07-21
CN110582296B (zh) 2024-02-06
EP3538143A1 (en) 2019-09-18
US20240115687A1 (en) 2024-04-11
CA3043039A1 (en) 2018-05-17
PH12019501019A1 (en) 2019-12-16
WO2018089841A1 (en) 2018-05-17
KR20190084097A (ko) 2019-07-15
JP2019533710A (ja) 2019-11-21
EP4159231A1 (en) 2023-04-05
HUE060176T2 (hu) 2023-01-28
US11992522B2 (en) 2024-05-28
PL3538143T3 (pl) 2022-10-17
ES2926543T3 (es) 2022-10-26
EP3538143B1 (en) 2022-06-22
MX2022014984A (es) 2023-01-04
WO2018089841A9 (en) 2018-09-07
MX2019005499A (es) 2019-07-04
KR102674702B1 (ko) 2024-06-14
AU2017357813A1 (en) 2019-06-27
CN110582296A (zh) 2019-12-17
RS63524B1 (sr) 2022-09-30
DK3538143T3 (da) 2022-08-29

Similar Documents

Publication Publication Date Title
BR112019009399A2 (pt) atenuação da virulência bacteriana por atenuação do transporte de folato bacteriano
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
PH12021550542A1 (en) Multivalent pneumococcal vaccines
NZ595689A (en) Compositions for immunising against staphylococcus aureus
BR112013027541A2 (pt) nanotransportadores sintéticos tolerogênicos
WO2015003816A3 (en) Cystobactamides
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
MX2020012061A (es) Composiciones que comprenden cepas bacterianas.
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
WO2018165765A9 (en) Probiotic molecules for reducing pathogen virulence
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
BR112017023636A2 (pt) suplemento dietético
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
EA201791401A1 (ru) СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЁННОГО КИШЕЧНИКА С ПРЕОБЛАДАНИЕМ ДИАРЕИ С ПРИМЕНЕНИЕМ Bacillus coagulans SBC37-01, MTCC 5856
PH12018501822A1 (en) Immune development accelerator
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
EP4349367A3 (en) A vaccine for protection against streptococcus suis
MX2022003871A (es) Composiciones inmunogénicas.
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]